123947-83-1

Basic information

• Product Name: 4-(3,4-dimethoxyphenoxy)butanoic acid
• CAS NO: 123947-83-1
• Molecular Formula: C₁₂H₁₆O₅
• Molecular Weight: 240.2524
• Mol File: 123947-83-1.mol

Chemical Properties

• Boiling Point: 418.089°C at 760 mmHg
• Flash Point: 160.012°C
• Density: 1.169g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.513
• CAS DataBase Reference: 4-(3,4-dimethoxyphenoxy)butanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-dimethoxyphenoxy)butanoic acid(123947-83-1)
• EPA Substance Registry System: 4-(3,4-dimethoxyphenoxy)butanoic acid(123947-83-1)

Safety Data

• Hazardous Substances Data: 123947-83-1(Hazardous Substances Data)

Upstream product

• 2033-89-8 3,4-dimethoxyphenol 
• 2969-81-5 Ethyl 4-bromobutyrate 

Downstream Products

• 123947-65-9 1-(7,8-dimethoxy-2,3-dihydro-1-benzoxepin-4-carbonyl)-4-(3, 4,5-trimethoxybenzoyl)piperazine 

Relevant articles and documents

Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives

During the screening of novel platelet-activating factor (PAF) antagonists, we found that 1-(6-methoxy-3,4-dihydro-2-naphthoyl)-4-(3,4,5- trimethoxybenzyl)piperazine and its 4-(3,4,5-trimethoxybenzoyl)piperazine derivatives (1b, 2b) exerted in vitro and i

PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof

Platelet Activating Factor (PAF) antagonists which comprises the compounds of the formula (I): wherein A is an optionally substituted phenyl or an optionally substituted heterocyclic group; X is methylene group, carbonyl group or thiocarbonyl group; R1, R2 and R3 are independently a lower alkyl group, and their salts are excellent in absorption from the intestinal canal. Among the compounds of the formula (I), those wherein A is an optionally substituted 2,3-dihydro-1-benzoxepin-4--yl group are novel compounds and exhibit excellent PAF antagonism.

PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof

Platelet Activating Factor (PAF) antagonists which comprise the compounds of the formula (I): STR1 wherein A is an optionally substituted phenyl or an optionally substituted heterocyclic group; X is methylene group, carbonyl group or thiocarbonyl group; R1, R2 and R3 are independently a lower alkyl group, and their salts are excellent in absorption from the intestinal canal. Among the compounds of the formula (I), those wherein A is an optionally substituted 2,3-dihydro-1-benzoxepin-4-yl group are novel compounds and exhibit excellent PAF antagonism.

The Preparation of 3,4-Dihydro-1-benzoxepin-5(2H)-ones

Several methods for the preparation of 3,4-dihydro-1-benzoxepin-5(2H)-ones are described.In addition to the desired ketones, a veriety of novel by-products have been isolated.